Tianjin Biopharmaceutical Innovation Park To Start Operation In April
This article was originally published in PharmAsia News
Executive Summary
China's biopharmaceutical international innovation park, sited in Tianjin Economic-Technological Development Area, has completed its phase one construction and will go into operation in April. To date, the park has received more than 170 domestic and overseas applications of R&D projects; it has already confirmed the location of four industrial companies with investment of over RMB100 million ($14.61 million) each. Tianjin International Biomedical Research Institute, the park's core component, will by year end establish a series of technical platforms including its clinical trial center, drug analysis and testing center, and information center. By the end of 2010, the park will be a world-class biopharmaceutical R&D base with more than 100 R&D teams and 1,000 people. (Click here for more - Chinese Language)
You may also be interested in...
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Report Finds Digital Diabetes Tools Deliver No ‘Meaningful Clinical Benefits'
A new report from health economics group the Peterson Health Technology Institute found that apps to help patients manage their blood sugar levels delivered few of the promised benefits. However, a digital therapeutics industry association says PHTI’s research cast too narrow a net.